Fallon Health Partners With RX Savings Solutions

January 7, 2021

Fallon Health, based in Worcester, MA, is a nationally recognized not-for-profit health care services organization, has partnered with Rx Savings Solutions, the market leader tool for pharmacy transparency that enables more cost-effective decision making, to help their eligible Medicare Advantage members save money on prescription drugs.

Fallon is the first health plan in the region to launch the patented solution to a Medicare Advantage population. Rx Savings Solutions connects securely with a member’s drug claim records and prepares a personalized prescription savings plan. When there is an opportunity for members to save, Rx Savings Solutions alerts them by text, email or direct mail. This real-time information helps pinpoint drug savings opportunities customized for a particular member in an effort to help them save on their drug costs.

“The rising cost of prescription drugs can have a serious impact on the personal finances of our Medicare Advantage members. And navigating the complex pharmacy system can be challenging,” said Carolyn Langer, M.D., Chief Medical Officer for Fallon Health. “Collaborating with Rx Savings Solutions provides greater transparency that makes it much easier for our Medicare Advantage members to find more affordable medications that are clinically effective.”

Serving more than 8 million members, Rx Savings Solutions’ clinical engine contains over 30,000 unique and dose-adjusted suggestions, used to drive proven savings results for health plans and their members. With differentiating features such as Contact Prescriber, members can submit a new prescription request to their provider with one click.

“We are delighted to partner with Fallon Health and provide their Medicare Advantage population with a platform that offers proactive prescription advice that delivers the best health and benefits experience at the lowest cost,” said Michael Rea, a clinical pharmacist who founded and currently leads Rx Savings Solutions. “We share in their mission of making our communities healthy, both physically and financially.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”